UCB's Nayzilam, or midazolam, nasal spray has been approved by the FDA for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that differ from usual seizure patterns in patients with epilepsy who are at least 12 years old. A late-stage study demonstrated treatment was associated with higher likelihood of seizure termination within 10 minutes of dosing and the absence of recurrence within six hours of initial dosing, compared with placebo.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.